Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

NA-Selank Amidate peptide icon, one bubble per amino acidNA-Selank Amidate7 residuesTKPRPGPEach bubble = one amino acid. Size = residue mass. Color = chemical class.

NA-Selank Amidate

Beginner tier: 200 mcg, daily · community consensus

CognitiveResearch
~2-3 min half-life·Nasal

Also known as: NA-Selank, N-Acetyl Selank, Selank Amidate

Zero PubMed-indexed studies exist for NA-Selank Amidate specifically. Every efficacy claim traces back to native Selank, the Russian-approved anxiolytic heptapeptide. What the dual modification (N-acetylation plus C-amidation) adds is enzymatic stability. Native Selank vanishes from plasma in 2 to 3 minutes; the amidate form sustains functional effects for an estimated 4 to 6 hours. The parent compound matched medazepam for anxiety reduction in a 62-patient GAD trial [1]. Hundreds of reports across r/nootropics describe it as "benzodiazepine-like calm without the fog." Administered intranasally, no needles required.

What Is NA-Selank Amidate?

NA-Selank Amidate (N-Acetyl Selank Amidate) is a stabilized derivative of Selank with anxiolytic properties that community users compare to benzodiazepines, minus the sedation, tolerance, or dependence. Hundreds of reports across r/nootropics and r/peptides describe that profile consistently.

NA-Selank Amidate is built on Selank, itself a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg). The N-terminal acetylation protects against aminopeptidases. The C-terminal amidation blocks carboxypeptidase degradation. Together, these modifications extend functional duration from minutes to hours after intranasal delivery.

The parent compound Selank has real clinical backing. Zozulia and colleagues tested it against medazepam in 62 patients with generalized anxiety disorder over 28 days [1]. Selank matched the benzodiazepine for anxiolytic effect while adding antiasthenic and mild nootropic properties the drug comparator lacked. Separate preclinical work confirmed BDNF upregulation in the hippocampus after intranasal dosing [2] and measurable cytokine modulation under stress conditions [3].

Community protocols have adapted to the amidate form's longer half-life. Most users dose once daily at 300 to 400 mcg intranasally for 14-day courses, then take a 14 to 21 day washout. The most popular stack pairs it with NA-Semax Amidate, morning Selank for anxiolytic baseline plus morning Semax for dopaminergic focus.

Formal clinical research covers native Selank only. The amidate modification uses sound mechanistic logic, but no human pharmacokinetic study has confirmed the assumed half-life extension.

How NA-Selank Amidate Works

NA-Selank Amidate operates through four converging pathways, all documented for the parent compound Selank in preclinical and limited clinical research.

The first pathway accounts for the anxiolytic effect. Selank is a subtype-selective positive allosteric modulator of GABA-A receptors. It increases inhibitory neurotransmission without directly binding the benzodiazepine site. That distinction matters; it explains the absence of sedation, amnesia, and physical dependence that define classical benzodiazepine use.

The second pathway involves endogenous opioid regulation. Selank inhibits enkephalin-degrading enzymes (enkephalinases) in blood plasma with an IC50 of approximately 15 micromolar [4]. Blocking enkephalin breakdown raises endogenous enkephalin levels, contributing to mood stabilization and mild analgesia.

Third, intranasal Selank administration upregulates BDNF mRNA and protein expression in the hippocampus. Inozemtseva and colleagues confirmed this in vivo [2]. BDNF-driven synaptic plasticity underpins the memory consolidation and neuroprotective effects that emerge by the second week of daily dosing.

Fourth, Selank-derived peptides modulate over 30 inflammation-related genes in immune tissue. Yasenyavskaya's group tracked reduced IL-6, IL-1-beta, and TNF-alpha alongside restored anti-inflammatory IL-4 under social stress conditions [3]. This dual neuro-immune mechanism is the basis for Selank's stress-protective properties.

The N-acetyl and C-amide modifications on NA-Selank Amidate do not change these mechanisms. They slow enzymatic degradation, extending the window during which the peptide remains active after each dose.

NA-Selank Amidate Benefits

  • NA-Selank Amidate benefits center on anxiolytic and nootropic effects, with immunomodulatory properties layered underneath.
  • Anxiolytic effect without sedation or dependence. The parent compound matched medazepam in a 62-patient GAD trial [1] while preserving full mental clarity.
  • BDNF upregulation in the hippocampus confirmed in vivo after intranasal dosing [2]. Users consistently report improved memory recall and learning speed emerging by week 2 of daily use.
  • Rapid onset sets it apart from most nootropics. Community reports converge on 15 to 30 minutes to first anxiolytic effect intranasally, with peak activity at 1 to 2 hours.
  • Pro-inflammatory cytokine reduction (IL-6, IL-1-beta, TNF-alpha) under stress conditions, with restored IL-4 levels [3]. This dual immune modulation supports long-term stress resilience.
  • Effects persist 5 to 7 days after a 14-day course ends. Community users consistently describe a residual anxiolytic and cognitive benefit window that outlasts the peptide's clearance, likely driven by BDNF-mediated neuroplasticity changes.
  • Enkephalinase inhibition raises endogenous enkephalin levels (IC50 ~15 micromolar)[4], contributing to mood stabilization through the body's own opioid system.

NA-Selank Amidate: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 6 key studies·Research only

No direct clinical or preclinical studies exist for NA-Selank Amidate as a distinct compound.

Dosing studied: 200-600 mcg/day intranasal (extrapolated from native Selank; no direct study data for this compound)
Read the evidence (key study, limitations)

Efficacy and safety data are entirely extrapolated from native Selank. The dual N-acetylation + C-amidation modification is supported mechanistically (protects against aminopeptidase and carboxypeptidase degradation) but has not been validated in human pharmacokinetic or clinical trials.

Key Study

Zozulia et al. 2008 (PMID 18454096): native Selank vs. medazepam in generalized anxiety disorder (n=62, 28-day trial); Selank showed comparable anxiolytic efficacy with additional antiasthenic effects. Not specific to NA-Selank Amidate.

Limitations

Zero PubMed-indexed studies for NA-Selank Amidate specifically. Phase-3 research status applies to native Selank (Russian MoH approval 2009), not this compound. Half-life extension (~4-6 hrs estimated) is mechanistically supported but unmeasured in humans. Most recent primary Selank research: PMID 32621722 (2021 cytokines/stress model); no new 2022-2026 primary studies found.

Community Experience
Moderate
3.9/5
Based on hundreds of reports across r/nootropics and r/peptides

Well-regarded anxiolytic in the nootropics community.

Community dosing: 200-500 mcg per session, once daily intranasal (extended half-life of amidate form supports once-daily dosing)
Read the reports (what users report 5, common issues 4)

Consistently described as "benzodiazepine-like calm without the fog." Widely stacked with NA-Semax Amidate. Community has pragmatically adopted the extended half-life by dosing once daily vs. native Selank's 3x/day.

What users report (5)
  • Anxiolytic effect without sedation or dependence: "benzodiazepine-like calm without the fog" (most consistently reported)
  • Rapid onset 15-30 min intranasal; sustained clarity and reduced anxiety for 4-6 hrs
  • BDNF-mediated memory and learning improvements emerging by week 1-2 of daily use
  • Stress resilience: blunted emotional reactivity to daily stressors with regular dosing
  • Effects reported to persist 5-7 days after end of 14-day course
Common issues (4)
  • Storage failure: opened spray degrades at room temperature; "it stopped working" most commonly traced to improper refrigeration
  • Protocol confusion: community debates 14-day vs. 4-week cycles and per-nostril vs. total-dose labeling (can double actual dose)
  • Paradoxical anxiety or mood changes in a minority, typically at supra-therapeutic doses or with accumulated GABA-A desensitization
  • Mild nasal irritation or transient headache in some users (usually resolves within first few days)
Partially Aligned

Community protocols (once-daily dosing, 14-day cycles) are better calibrated to the extended half-life of the amidate form than the 4-week cycle listed here. Scientific literature covers native Selank only; community application to the amidate modification uses reasonable mechanistic extrapolation but lacks direct validation.

NA-Selank Amidate Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDoseFrequency
Beginner200 mcgDaily
Moderate400 mcgDaily
Aggressive600 mcgDaily
Note:

Most NA-Selank Amidate comes as a pre-mixed nasal spray, so reconstitution typically isn't needed. If you're working with lyophilized powder (10 mg vial), add 10 mL bacteriostatic water for a 1 mg/mL concentration. Each unit on a U100 insulin syringe then delivers 10 mcg. So 200 mcg is 20 units, 300 mcg is 30 units, 500 mcg is 50 units.

The per-nostril versus total-dose labeling trap catches more beginners than any other issue. A standard 300 mcg/pump spray, one pump per nostril, delivers 600 mcg total. That's an aggressive dose on day one. Start with one pump total per session, not per nostril.

Refrigerate the spray the moment you open it. "It stopped working" is the single most common troubleshooting complaint in the community; the cause is almost always room-temperature storage. Opened sprays degrade fast and should be used within 30 days.

If you notice the anxiolytic effect weakening before day 14, don't increase the dose. End the course early and extend your washout to 3 weeks. The amidate form's longer receptor occupancy may speed up GABA-A desensitization compared to native Selank.

Cycling Protocol

On Period
4 weeks
Off Period
2 weeks

Russian clinical protocols for Selank use 14-day treatment courses intranasally 3 times daily. Many practitioners extend this to 4-week cycles with 2-week washout periods. The anxiolytic effect has been reported to persist for approximately one week after the last dose. No tolerance or dependence has been observed with repeated cycles. Some users employ continuous low-dose use (200 mcg 1-2x daily) without cycling.

Calculate your NA-Selank Amidate dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

NA-Selank Amidate Protocols by Goal

beginnerCommunity14 days on, 14 days off minimum
Treatment Course
Wk 2
200-300 mcg · Once daily · Intranasal

Expected: Consistent anxiolytic effect by day 3-5; mild sleep quality improvements; effects may persist 5-7 days after last dose

Monitor: Note any paradoxical anxiety or unusual mood changes and discontinue if present. Monitor for sedation if co-using any GABAergic medication.

How to Use NA-Selank Amidate

  1. 1
    Clear your nasal passages before dosing

    Blow your nose gently; you want clear airways for absorption.

  2. 2
    Prime the spray pump if it's a new bottle

    Point away from your face and pump 2 to 3 times until you see a fine mist.

  3. 3
    Tilt your head slightly forward

    Insert the spray tip into one nostril. Depress the pump once while inhaling gently through your nose.

  4. 4
    For beginners: one pump total per session (not per nostril)

    A standard spray delivers approximately 300 mcg per pump. One pump is your full dose.

  5. 5
    Step 5

    For the intermediate protocol: one pump per session for 3 to 4 days, then increase to 300 to 500 mcg once daily if well tolerated.

  6. 6
    Dose in the morning

    If using twice daily on high-demand days, keep doses at least 5 hours apart and avoid dosing after 3 PM to prevent sleep interference.

  7. 7
    Step 7

    Do not blow your nose for 10 to 15 minutes after application.

  8. 8
    Step 8

    If using reconstituted lyophilized powder with an intranasal atomizer device (MAD) instead of pre-mixed spray: 10 mg vial plus 10 mL BAC water gives 1 mg/mL. Draw 20 units for 200 mcg, 30 units for 300 mcg, 50 units for 500 mcg. Administer via MAD attached to a 1 mL syringe.

  9. 9
    Onset of anxiolytic effects occurs within 20 to 40 minutes

    Peak effects at 1 to 2 hours.

  10. 10
    Store opened spray at 2 to 8 degrees Celsius

    Discard after 30 days.

Alternative Routes

Intranasal spray (pre-mixed solution)

Standard reference dose; 200-500 mcg per session

Verify mcg per pump from spray concentration before first use. Standard pre-mixed sprays: 300 mcg/pump at 1.5 mg/mL is common. Refrigerate immediately after opening.

Subcutaneous injection (reconstituted lyophilized powder)

250-500 mcg per injection, once daily; total daily dose comparable to intranasal route

No head-to-head bioavailability comparison between routes for Selank family peptides. Subcutaneous allows more precise volume control than pump sprays. Reconstitute 10mg vial with 10mL BAC water for 1 mg/mL (200 mcg = 20 units U100). Intranasal atomizer device (MAD) can also be used with reconstituted solution.

Sublingual

Unknown: no comparative data; inconsistent community reports

Not a validated or commonly recommended route for Selank family peptides.

NA-Selank Amidate Stacking Protocols

Works With

Avoid

Benzodiazepines (diazepam, alprazolam, lorazepam)

Selank potentiates diazepam effects in preclinical models; combination risks over-sedation and additive CNS depression. Mechanistically contraindicated.

Do not combine
SSRIs / SNRIs

No clinical interaction data. Selank modulates serotonin metabolism and GABA in animal models: overlapping mechanisms with antidepressants. Community consensus: cautious; warrants physician guidance before combining.

GABAergic drugs (gabapentin, pregabalin, barbiturates, alcohol)

Additive CNS depressant effects via shared GABA-A modulation. Alcohol also counteracts nootropic and neuroprotective benefits.

Antihypertensives

Selank produces transient blood pressure reduction in animal studies; potential additive hypotensive effect if on antihypertensive medication.

Estimated Cost

Generic / Research
Lyophilized powder 10mg: ~$38-60 USD (typical research-grade price)
Compounded
Pre-mixed nasal spray 10mL/10mg: ~$45-75 USD; 15mL/30mg spray: ~$70-100 USD (typical research-grade prices)

Pricing updated 2026-04-09

NA-Selank Amidate Side Effects

No direct human safety data exists for NA-Selank Amidate as a distinct compound. Every safety profile detail below comes from native Selank studies or community reports of the amidate form. That evidence gap matters, because the extended half-life could change the side effect profile in ways that haven't been formally measured.

The most clinically relevant concern is serotonergic overlap. Selank modulates serotonin metabolism and GABA activity in animal models. Anyone on SSRIs, SNRIs, or other serotonergic medications faces a theoretical interaction with no clinical data to quantify the risk. Increased sedation and serotonin-adjacent symptoms are the signals to watch for. Talk to your prescriber before combining.

Benzodiazepine potentiation is documented preclinically. Selank amplifies diazepam's effects in animal models. Combining the amidate form with any benzodiazepine (diazepam, alprazolam, lorazepam) risks excessive sedation and additive CNS depression. This is a hard contraindication at anything above minimum doses.

Paradoxical anxiety affects a minority of users, typically at doses above 500 mcg or after prolonged use without cycling. This reflects GABA-A receptor desensitization rather than a serotonergic mechanism. Reduce to 200 mcg; discontinue if it persists at that dose.

Transient blood pressure reduction is observed in animal studies, lasting 1 to 3 minutes post-dose. Clinically, this matters only if you're on antihypertensives or prone to orthostatic hypotension. Check blood pressure with your first few doses.

Mild nasal irritation or brief burning at the application site is the most common complaint. Occasional fatigue or drowsiness occurs in sensitive users. Transient headache in the first 1 to 3 days is reported by some; community users find Alpha-GPC (300 mg) mitigates this.

Native Selank clinical trials (up to 28 days of daily dosing) reported no dependence, withdrawal, amnesia, or sedation. No toxicity emerged in studies running one month of continuous administration.

Contraindications: pregnancy or breastfeeding (no safety data), known hypersensitivity to Selank, tuftsin, or formulation components, severe hypotension, active nasal infections or recent nasal surgery, children under 18, and autoimmune conditions where immunomodulatory effects could alter immune balance.

When to stop and contact a physician: paradoxical anxiety that persists at reduced doses, excessive sedation (especially if using other GABAergic substances), signs of serotonin-like effects (agitation, tremor, hyperthermia) if on antidepressants, or symptomatic hypotension.

Common Issues & Solutions

Spray "stopped working": most commonly storage failure: opened sprays must be refrigerated (2-8C) and used within 30 days; room-temperature storage causes significant potency loss and is the #1 reported cause of non-response.

Per-nostril vs. total dose confusion: always confirm spray label: "200 mcg per nostril" vs "200 mcg total per session" doubles actual dose. At 300 mcg/pump, one pump per nostril = 600 mcg total; start with one pump total per session.

Tolerance developing before day 14: end course at first sign of diminishing anxiolytic response and extend washout to 3 weeks; the amidate form's longer half-life may accelerate GABA-A desensitization vs. native Selank.

Paradoxical anxiety or agitation: reduce to 200 mcg; more common at doses above 500 mcg; reflects receptor desensitization rather than serotonergic effect; discontinue if it persists at low doses.

Mild headache within 2 hrs of dosing: often responds to choline supplementation (Alpha-GPC 300 mg); if persistent, reduce dose and ensure adequate hydration.

Ask AI about this page

Ask AI for a second opinion on NA-Selank Amidate dosing and side effects

Contraindications

  • Pregnancy or breastfeeding: no safety data available
  • Known hypersensitivity to Selank, tuftsin, or any component of the formulation
  • Severe hypotension: transient blood pressure reduction observed in animal models
  • Active nasal infections, nasal polyps, or recent nasal surgery: may impair absorption
  • Children under 18: not studied in pediatric populations
  • Autoimmune conditions: immunomodulatory effects may theoretically alter immune balance

Drug Interactions

  • Benzodiazepines (diazepam, alprazolam, lorazepam): Selank enhances diazepam effects in preclinical models; may potentiate sedation if combined at higher doses
  • Antihypertensives: additive blood pressure lowering possible given Selank's transient hypotensive effect in animal studies
  • Opioid analgesics: Selank inhibits enkephalinase and may alter endogenous opioid peptide levels; theoretical interaction
  • Immunosuppressants (cyclosporine, tacrolimus): Selank modulates cytokine expression and immune gene activity; may alter immunosuppressive balance
  • GABAergic drugs (gabapentin, pregabalin, barbiturates): potential for additive CNS depressant effects via GABA-A modulation
  • Alcohol: may counteract nootropic and neuroprotective effects; avoid concurrent use
  • Selank produces transient blood pressure reduction in animal studies; potential additive hypotensive effect if on antihypertensive medication.

Product Quality

Recommended Monitoring

TestWhenTarget
Blood pressureFirst 1-3 doses; ongoing if on antihypertensivesNo specific numeric target: monitor for symptomatic hypotension (lightheadedness, dizziness within 5-15 min of dose)
Subjective anxiety and mood logDaily throughout 14-day courseNot listed
Blood pressure

Transient hypotensive effect observed in animal studies; clinically relevant if taking antihypertensives or prone to orthostatic hypotension

Subjective anxiety and mood log

Early detection of tolerance (diminishing anxiolytic effect) and rare paradoxical anxiety response; guides whether to continue or end course and extend washout

NA-Selank Amidate Before and After

First dose
20-60 min

Rapid onset of mild anxiolytic effects within 20-40 minutes of intranasal administration. Subtle sense of calm and reduced mental tension. Some users report improved mental clarity and verbal fluency within the first hour. Effects peak at 1-2 hours post-dose.

Days 1-3

Anxiolytic effects become more consistent with regular dosing. Reduced reactivity to daily stressors. Mild improvements in focus and attention. Sleep quality may improve as baseline anxiety decreases.

Days 4-7

Nootropic effects emerge: improved memory recall, faster information processing, and better sustained attention. BDNF upregulation is underway. Mood stabilization and reduced irritability become more noticeable.

Weeks 2-4

Full anxiolytic and nootropic benefits develop. Significant reduction in generalized anxiety comparable to low-dose benzodiazepines. Enhanced learning capacity and memory consolidation. Immunomodulatory effects (reduced inflammatory cytokines) contribute to improved overall well-being and stress resilience.

After cycling off

Anxiolytic effects persist for approximately 5-7 days after the last dose. Cognitive improvements driven by BDNF-mediated neuroplasticity may persist longer. No withdrawal symptoms, rebound anxiety, or dependence reported. Cycle can be repeated after a 2-week break.

What to Expect

First dose (20 to 60 minutes): You'll notice a mild but clear anxiolytic shift within 20 to 40 minutes of intranasal dosing. Think quieted mental chatter rather than sedation. Verbal fluency and mental clarity pick up for some users within the first hour. Effects peak at 1 to 2 hours. Mild nasal irritation is possible; brief lightheadedness from transient blood pressure reduction is rare and resolves within minutes.

Days 1 to 5: The calming baseline becomes more reliable with daily dosing. Stressors that triggered disproportionate reactions feel more manageable. Sleep often improves as anxious arousal drops. Some users get a transient headache in days 1 to 3; Alpha-GPC (300 mg) tends to resolve it.

Days 6 to 14: This is the window where nootropic effects layer on top of the anxiolytic base. Memory recall sharpens, information processing speeds up, and sustained attention improves. These changes reflect BDNF upregulation in the hippocampus reaching functional levels. Mood stabilization and reduced irritability become distinct from the acute anti-anxiety effect. Most community users call this the peak benefit window of a 14-day course.

After cycling off: Direct GABA-A modulation clears within hours. The anxiolytic and mood benefits persist for roughly 5 to 7 days after your last dose. Cognitive improvements driven by BDNF-mediated neuroplasticity may last 1 to 2 weeks beyond that. No withdrawal symptoms, rebound anxiety, or dependence signs. Repeat the cycle after a minimum 14-day break.

Detailed Timeline: Science vs Community

First dose (20-60 min)
Science

Rapid GABA-A positive allosteric modulation following intranasal absorption (plasma detectable within 15-30 min per native Selank PK data). Enkephalinase inhibition begins within minutes of systemic exposure.

Community

Mild but noticeable calm within 20-40 min; reduced mental tension and quieting of anxious thought patterns. Some users report improved verbal fluency and mental clarity within the first hour. Effects peak at 1-2 hrs.

Days 1-5
Science

Cumulative GABA-A modulation and sustained enkephalin elevation building. BDNF mRNA upregulation initiating in hippocampus (animal data: detectable within first days of daily intranasal dosing).

Community

More consistent baseline calm; reduced reactivity to daily stressors; mild sleep quality improvements as anxious arousal decreases. Transient headache in days 1-3 for some users.

Days 6-14
Science

BDNF-mediated synaptic plasticity and memory consolidation developing; cytokine modulation (reduced IL-6, IL-1beta, TNF-alpha; restored IL-4) measurable in preclinical stress models by days 7-14.

Community

Improved memory recall, faster information processing, better sustained attention. Mood stabilization and reduced irritability. Many users report this as the peak benefit window of the 14-day course.

After cycling off
Science

Direct GABA-A modulation dissipates within hours as peptide clears. BDNF-driven neuroplasticity changes (synaptic strengthening) are more durable and persist beyond peptide clearance.

Community

Anxiolytic and mood benefits reported to persist 5-7 days post-last-dose. Cognitive improvements (memory, clarity) sometimes reported for 1-2 weeks. No withdrawal, rebound anxiety, or dependence reported.

Pharmacokinetics

Half-Life
3min
Bioavailability
Intranasal: rapid absorption through nasal mucosa with detectable plasma levels within 15-30 minutes
Tmax
~20-40 min (intranasal); peak effects at 1-2 hours
Data Confidence
low

Source: Plasma t½ ~2-3 minutes for native Selank. NA-Selank Amidate has improved enzymatic stability due to N-acetylation and C-amidation, likely extending effective t½ somewhat. Functional anxiolytic and nootropic effects persist 6-8 hours due to downstream gene expression changes (BDNF upregulation, cytokine modulation) and enkephalinase inhibition.

Pharmacokinetics: Active Dose Over Time

t½ = ~2-3 min (plasma); functional effects persist 6-8 hours via downstream gene expression

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
7
Sequence
TKPRPGP
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: No confirmed CAS for the dual-modified form; native Selank CAS: 129954-34-3

Who Should Consider NA-Selank Amidate

  • Adults with generalized anxiety disorder seeking non-benzodiazepine anxiolytic options
  • Individuals experiencing chronic stress with associated cognitive impairment
  • Those seeking nootropic support for memory, focus, and learning without stimulant side effects
  • People with stress-related immune dysregulation or elevated inflammatory markers
  • Individuals looking for an anxiolytic without sedation, tolerance, or dependence risk
  • Those recovering from chronic alcohol-related cognitive impairment

Related Peptides

What Changed for NA-Selank Amidate

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations

References

  1. [1]Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in therapy of GAD and neurasthenia (Zozulia et al. 2008) (opens in a new tab)PubMed (opens in a new tab)Clinical Trial
  2. [2]Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo (Inozemtseva et al. 2008) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]The influence of Selank on the level of cytokines under conditions of social stress (Yasenyavskaya et al. 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity (Zozulya et al. 2001) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store lyophilized powder at -20°C for long-term or 2-8°C for up to 12 months
After Reconstitution
Pre-mixed nasal spray: store at 2-8°C, use within 30 days once opened
Temperature
Protect from light and heat. Do not freeze reconstituted nasal spray.

Frequently Asked Questions

The dual modification (N-acetyl + C-amide) extends the half-life from about 2-3 minutes to an estimated 4-6 hours, so you can dose once daily instead of three times. That said, no head-to-head human study exists comparing the two. You're paying for convenience, not proven superiority.

No clinical interaction data exists. Selank modulates serotonin and GABA in animal studies, which overlaps with SSRI mechanisms. Start low, watch for increased sedation or serotonin-like effects, and talk to your prescriber before combining.

Because it can double your actual dose without you realizing it. A standard 200 mcL pump at 0.15% concentration delivers about 300 mcg per spray. One pump per nostril = 600 mcg total, not 300. Always verify your spray volume and concentration before dosing.

Community theory says yes: longer receptor occupancy from the extended half-life may speed up GABAergic desensitization. That's why some users recommend 14-day cycles for the amidate form instead of the typical 28 days used for native Selank.

You'll get acute anxiolytic effects from as-needed use through its GABA-A activity. But the lasting cognitive and neuroprotective benefits from BDNF and cytokine modulation only come from running a full 14-day course. As-needed use is basically treating symptoms without building the underlying resilience.